Diroximel fumarate
![]() | |
Names | |
---|---|
Trade names | Vumerity |
Other names | ALKS-8700 |
Clinical data | |
Main uses | Relapsing forms of multiple sclerosis (MS)[1] |
Side effects | Flushing, abdominal pain, diarrhea, nausea[1] |
Routes of use | By mouth |
External links | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620002 |
Legal | |
License data | |
Legal status | |
Chemical and physical data | |
Formula | C11H13NO6 |
Molar mass | 255.226 g·mol−1 |
3D model (JSmol) | |
| |
|
Diroximel fumarate, sold under the brand name Vumerity, is a medication used to treat relapsing forms of multiple sclerosis (MS).[1] This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1] It is taken by mouth.[1]
Common side effects include flushing, abdominal pain, diarrhea, and nausea.[1] Other side effects may include anaphylaxis, progressive multifocal leukoencephalopathy, herpes zoster, liver problems, and low lymphocytes.[1] Use in pregnancy may harm the baby.[2] It works after the body converts it into monomethyl fumarate (MMF).[3]
Diroximel fumarate was approved for medical use in the United States in 2019.[3] While it was approved in Europe and the United Kingdom in 2021 it is not yet commercially available.[3] In the United States it costs about 7,900 USD per day as of 2021.[4]
Medical uses
It is used for the treatment of relapsing forms of multiple sclerosis (MS).[1][5][6]
Dosage
It is started at 231 mg twice per day for a week.[1] It is than taken as 462 mg twice per day.[1]
Society and culture
This drug was formulated by Alkermes in collaboration with Biogen.[7]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Vumerity- diroximel fumarate capsule". DailyMed. Archived from the original on 5 February 2021. Retrieved 1 February 2021.
- ↑ "Diroximel fumarate Pregnancy and Breastfeeding Warnings". Archived from the original on 14 February 2021. Retrieved 26 December 2021.
- ↑ 3.0 3.1 3.2 "Vumerity · Relapsing remitting multiple sclerosis (MS)". Archived from the original on 19 May 2021. Retrieved 26 December 2021.
- ↑ "Vumerity Prices, Coupons and Patient Assistance Programs". Retrieved 26 December 2021.
- ↑ Wang Y, Bhargava P (July 2020). "Diroximel fumarate to treat multiple sclerosis". Drugs of Today (Barcelona, Spain : 1998). 56 (7): 431–437. doi:10.1358/dot.2020.56.7.3151521. PMID 32648853.
- ↑ Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E (October 2020). "Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?". Pharmaceuticals (Basel, Switzerland). 13 (10): 306. doi:10.3390/ph13100306. PMC 7602023. PMID 33066228.
- ↑ "Archive copy". Archived from the original on 28 August 2021. Retrieved 30 July 2021.
{{cite web}}
: CS1 maint: archived copy as title (link)
External links
Identifiers: |
|
---|
- "Diroximel fumarate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 28 August 2021. Retrieved 30 July 2021.
- Pages using duplicate arguments in template calls
- CS1 maint: archived copy as title
- Use American English from February 2021
- Articles with invalid date parameter in template
- All Wikipedia articles written in American English
- Use dmy dates from February 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs not assigned an ATC code
- Articles with specifically marked weasel-worded phrases from October 2020
- Multiple sclerosis
- Imides
- Esters
- Methyl esters
- Fumarate esters
- All stub articles
- Pharmacology stubs